NO20085331L - Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer - Google Patents

Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer

Info

Publication number
NO20085331L
NO20085331L NO20085331A NO20085331A NO20085331L NO 20085331 L NO20085331 L NO 20085331L NO 20085331 A NO20085331 A NO 20085331A NO 20085331 A NO20085331 A NO 20085331A NO 20085331 L NO20085331 L NO 20085331L
Authority
NO
Norway
Prior art keywords
pyrazolo
pyrimidines
cdk inhibitors
compounds
cdk
Prior art date
Application number
NO20085331A
Other languages
English (en)
Norwegian (no)
Inventor
Amin A Nomeir
Ronald J Doll
Timothy J Guzi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20085331L publication Critical patent/NO20085331L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20085331A 2006-05-22 2008-12-19 Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer NO20085331L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80257706P 2006-05-22 2006-05-22
PCT/US2007/011991 WO2007139732A1 (en) 2006-05-22 2007-05-21 Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors

Publications (1)

Publication Number Publication Date
NO20085331L true NO20085331L (no) 2009-02-19

Family

ID=38544151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085331A NO20085331L (no) 2006-05-22 2008-12-19 Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer

Country Status (18)

Country Link
US (1) US20070275963A1 (es)
EP (1) EP2027127A1 (es)
JP (1) JP2009538304A (es)
KR (1) KR20090019796A (es)
CN (1) CN101495481A (es)
AR (1) AR061072A1 (es)
AU (1) AU2007268083A1 (es)
BR (1) BRPI0712016A2 (es)
CA (1) CA2653076A1 (es)
EC (1) ECSP088906A (es)
IL (1) IL195238A0 (es)
MX (1) MX2008014824A (es)
NO (1) NO20085331L (es)
PE (1) PE20080071A1 (es)
RU (1) RU2008150419A (es)
TW (1) TW200817404A (es)
WO (1) WO2007139732A1 (es)
ZA (1) ZA200809796B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091195A1 (es) * 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
CA2773854A1 (en) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2833288A1 (en) * 2011-04-19 2012-10-26 Bayer Intellectual Property Gmbh Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014089379A1 (en) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015092707A2 (en) * 2013-12-17 2015-06-25 Csir A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
RU2633032C1 (ru) * 2016-05-23 2017-10-12 Общество с ограниченной ответственностью "Новые научные технологии" Новые ингибиторы серин-треониновых киназ, в том числе для лечения онкологических заболеваний и туберкулеза
WO2019154177A1 (zh) * 2018-02-12 2019-08-15 恩瑞生物医药科技（上海）有限公司 嘧啶类化合物、其制备方法及其医药用途
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN111393447B (zh) * 2020-05-14 2021-01-15 苏州信诺维医药科技有限公司 一种嘧啶并吡唑类化合物、其制备方法及应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025228376A1 (zh) * 2024-04-30 2025-11-06 阿诺医药 (新加坡) 有限公司 Cyclin K降解剂药物及其抗体偶联物
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537116B1 (en) * 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
CN1701073B (zh) * 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN101360499B (zh) * 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
US7776865B2 (en) * 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
IL195238A0 (en) 2009-08-03
CN101495481A (zh) 2009-07-29
CA2653076A1 (en) 2007-12-06
ZA200809796B (en) 2009-11-25
KR20090019796A (ko) 2009-02-25
TW200817404A (en) 2008-04-16
US20070275963A1 (en) 2007-11-29
WO2007139732A1 (en) 2007-12-06
EP2027127A1 (en) 2009-02-25
JP2009538304A (ja) 2009-11-05
MX2008014824A (es) 2008-12-01
BRPI0712016A2 (pt) 2011-12-27
RU2008150419A (ru) 2010-09-20
AU2007268083A1 (en) 2007-12-06
PE20080071A1 (es) 2008-02-11
ECSP088906A (es) 2008-12-30
AR061072A1 (es) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20085331L (no) Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer
NO20082091L (no) Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
PH12015500666A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MY188335A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MX2009003185A (es) Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
BR112012010041A2 (pt) derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
GT201000082A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
WO2007044407A3 (en) Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
TN2009000163A1 (en) Compounds and compositions as protein kinase inibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application